Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine

Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Okamura, Daisuke, Matsuda, Akira, Ishikawa, Maho, Maeda, Tomoya, Tanae, Ken, Kohri, Mika, Takahashi, Naoki, Kawai, Nobutaka, Asou, Norio, Bessho, Masami
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2014
Materias:
Case Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4009407/
https://ncbi.nlm.nih.gov/pubmed/24809010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2014.03.002
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares